Effect of high-intensity interval training on cardiovascular disease risk factors and body composition in psoriatic arthritis: a randomised controlled trial

Ruth Stoklund Thomsen,1,2 Tom Ivar Lund Nilsen,1,3 Glenn Haugeberg,4,5 Anja Bye,6,7 Arthur Kavanaugh,8 Mari Hoff1,2,4

ABSTRACT

Background Psoriatic arthritis (PsA) is associated with an accumulation of cardiovascular disease (CVD) risk factors. The aim of this study was to evaluate the effect of high-intensity interval training (HIIT) on CVD risk factors in patients with PsA.

Methods We randomly assigned 61 patients with PsA (41 women and 20 men) to an intervention group performing HIIT for 11 weeks or a control group who were instructed to not change their physical exercise habits. Outcomes were assessed at 3 and 9 months with measures on maximal oxygen uptake (VO$_{2\text{max}}$), fat percentage and Body Mass Index (BMI). We used linear mixed models to calculate mean difference with 95% CI between the groups according to the intention-to-treat principle.

Results At 3 months, the HIIT group had a 3.72 mL/kg/min (95% CI 2.38 to 5.06) higher VO$_{2\text{max}}$ and a 1.28 (95% CI −2.51 to −0.05) lower truncal fat percentage than controls. There was also some evidence that the HIIT group had lower total fat percentage (−0.80; 95% CI −1.71 to 0.10) and slightly lower BMI (−0.31; 95% CI −0.78 to 0.17) than the control group. At 9 months, the HIIT group had a 3.08 (95% CI 1.63 to 4.53) higher VO$_{2\text{max}}$ and 3.72% lower triglyceride levels (95% CI −0.43 to −7.88) compared with the control group. However, the difference in other factors was small.

Conclusion In patients with PsA, 3 months with HIIT was associated with a substantial increase in VO$_{2\text{max}}$ and a reduction in truncal fat percentage compared with controls. The beneficial effect on VO$_{2\text{max}}$ was also sustained through 9 months.

Trial registration number NCT02995460.

INTRODUCTION

Psoriatic arthritis (PsA) is an inflammatory chronic disease with manifestations such as arthritis, enthesitis, dactylitis and spondylitis. PsA is also associated with obesity, dyslipidemia and insulin resistance, key aspects of the metabolic syndrome, which increases patients’ risk of cardiovascular disease (CVD) and mortality.1–5

Cardiorespiratory fitness is known to be a strong, independent predictor for CVD and all-cause mortality in the general population.6–7 Measuring the maximal oxygen uptake (VO$_{2\text{max}}$) is considered the gold standard for assessing cardiorespiratory fitness, and it is carried out by a cardiopulmonary exercise test to exhaustion.8 VO$_{2\text{max}}$ commonly increases by an average of ~3%–35% with regular endurance training in a dose-dependent manner,9–11 and a 3.5 mL/kg/min increase in VO$_{2\text{max}}$ has been associated with 13% decreased risk of death from all causes.9 Studies have demonstrated that patients with arthritis, including PsA, have a reduced cardiorespiratory fitness, likely due to factors such as a more sedentary lifestyle.12–14
High-intensity interval training (HIIT) is a method of organising cardiorespiratory training with repeated bouts of short-duration, high-intensity exercise intervals at 80%–95% of maximum heart rate (HR_{max}) interrupted by periods of active recovery. Several studies have shown that HIIT increases cardiorespiratory fitness more than moderately intense physical exercise and is less time consuming.\cite{10.1136/rmdopen-2018-000729,15,16}

With the increased CVD morbidity and mortality in PsA, it is important to explore alternative methods to reduce the CVD risk factors since treatment with disease-modifying medication alone is insufficient. There is a paucity of evidence regarding the effects of physical exercise in PsA. Given many patients’ unfavourable CVD risk profile, it seems reasonable to recommend physical exercise.

The aim of this study was to evaluate the effect of HIIT on CVD risk factors such as cardiorespiratory fitness and body composition in patients with PsA. Furthermore, we aimed to see if any benefit was enduring beyond the study time.

**METHODS**

**Design**

We conducted a randomised controlled trial (RCT) with two parallel groups, comparing an intervention group performing HIIT three times per week for 11 weeks with a control group with no change in pre-study physical exercise habits. The study was conducted according to Good Clinical Practice and Declaration of Helsinki principles. Results are presented according to the Consolidated Standards of Reporting Trials statement.\cite{17}

**Participants**

To be eligible, patients with PsA needed to be between ages 18 and 65 years and fulfil the CASPAR (CLASsification for Psoriatic ARthritis) criteria. Exclusion criteria included patients with inability to exercise; patients with unstable ischaemic CVD or severe pulmonary disease; pregnancy; breast feeding; drug or alcohol addictions; and an anticipated need for a change in synthetic or biologic disease-modifying anti-rheumatic drugs (DMARDs) during the intervention period. However, a change of DMARDs was possible during the follow-up period from 3 to 9 months. A change in corticosteroid doses and intra-articular corticosteroid injections were allowed until 4 weeks before any follow-up. In addition, the investigator interviewed the participants about physical exercise habits. Those who reported vigorous endurance training like running, bicycling and so on once or more a week for the last 3 months were excluded. Participants were recruited through local advertisement at the Department of Rheumatology, St. Olavs Hospital; The Psoriasis and Eczema Association of Norway; and The Norwegian Rheumatism Association. The study was conducted at St. Olavs Hospital and NTNU–Norwegian University of Science and Technology, Trondheim, Norway from 2013 to 2015.

**Intervention**

The exercise intervention was performed as a supervised HIIT programme starting with a 10 min warm-up, followed by four times 4 min exercise at 85%–95% of HR_{max} interspersed by 3 min exercise at 70% of the HR_{max}.\cite{18} The supervised HIIT was performed on a stationary bicycle at CERG twice a week with an intermittent day of rest. The supervisors were experienced in guiding a HIIT, and one supervisor guided a maximum of six participants at a time. Additionally, the participants did one self-guided HIIT a week. They were instructed in using the HIIT concept by for example, running, bicycling or walking uphill. All exercises were supported by a heart rate monitor. During the period of follow-up from 3 to 9 months, the participants in the HIIT group were encouraged to keep on exercising, but without guidance. To reinforce adherence to the training programme, diaries were delivered by the HIIT group every week during the intervention period from baseline to 3 months and included information on the type of exercise, time, location and with whom it was performed. Moreover, the intensity was rated by the registered heart rate and by the 15-point Borg scale (from 6 to 20), the latter being a method of rating perceived exertion.\cite{21,22} During follow-up from 3 to 9 months, the HIIT group did not fill in diaries or collect data such as heart rates. Participants in the control group were instructed to not change their pre-study physical exercise habits. However, in the follow-up period from 3 to 9 months, they were encouraged to start exercising. Nevertheless, they were not given diaries or instruction regarding the Borg scale. Neither were they given any specific instructions in how to perform HIIT. At the 9-month follow-up, the investigator interviewed all participants. If they were reporting vigorous endurance training once or more a week, they were classified as ‘doing endurance exercise’.

**Cardiorespiratory fitness testing**

Maximal oxygen uptake (VO_{2max}) was assessed with a maximal bicycling test on an ergometer bike (Monark 839 Medical) using a portable metabolic measurement system for measurements of gas exchange and ventilation (MetaMax II).\cite{18} The test was initiated by a warm-up and proceeded by an increase in resistance and speed until subjects reached VO_{2max}. Levelling-off of oxygen uptake despite an increase in workload and respiratory exchange ratio >1.10 were used as a criteria for reaching VO_{2max}. The highest HR was recorded during the VO_{2max} test and HR_{max} was then calculated by adding five beats to that value.\cite{19} HR_{max} was used to calculate the required individual heart rate during the exercise intervention. All tests were performed at the Cardiac Exercise Research Group (CERG) by professionals with educational backgrounds in physiology and bioengineering, who were certified to do cardiorespiratory fitness testing by the CERG or NeXtMove facilities, NTNU.
Assessment of outcome measures and baseline data

Outcome measures were assessed at baseline, and at 3 and 9 months of follow-up. Demographics, comorbidities and medications used were obtained from the medical journal system and the GoTreatIT Rheuma computer tool25 (www.diagraphit.com).

Main outcome measure
VO_{2max} (mL/kg/min) was the main outcome and assessment was performed as described above.

Secondary outcome measures
Body Mass Index (BMI, kg/m²) was calculated based on measurements of height and weight assessed fasting in the morning at the Department of Research and Development, St. Olavs Hospital. Body composition measuring the proportion of fat and lean mass in the whole body was assessed using dual-energy X-ray absorptiometry (DXA) (GE Healthcare Lunar) registering total fat (%), truncal fat (%) and lean muscle mass (g) at the Department of Rheumatology, St. Olavs Hospital.24 25

Resting heart rate (HR), measured as beats/minute, was assessed repeatedly three times, registering the lowest value at the Department of Research and Development, St. Olavs hospital.

Sample size
A difference in the main outcome measure (VO_{2max}) of 3 mL/kg/min was considered clinically important, and based on a SD of 5.20 and a correlation of 0.4 between repeated measures, we estimated that 30 patients were required in each group to achieve a power of 90 at an alpha level of 0.05.

Randomisation and blinding
Patients were randomised to either a HIIT group or control group according to a 1:1 allocation in permuted blocks after the signed consent and clinical investigation using a computer random-number generator (Unit for Applied Clinical Research, St. Olavs Hospital). Participants were stratified according to sex. The block randomisation did not allow the investigator to reveal the next allocation. The assessors at the laboratory, at CERG, at the Department of Research and Development, and the Department of Rheumatology, St. Olavs Hospital were blinded for allocation.

Statistical analyses
The main analyses of both primary and secondary outcomes were conducted according to an intention-to-treat strategy using all available data from all time points. We used a linear mixed model for repeated measures to estimate mean difference with 95% CI in outcome variables within each group. All measures of effect were adjusted for sex (men, women) and age (continuous) to control for possible bias due to baseline imbalances in these factors.

The diaries were reviewed to find the number of accomplished supervised and self-guided exercises. The mean intensity referring to the Borg scale was calculated according to the values recorded in the diaries.

RESULTS

Participant flow and characteristics
A total of 102 patients were assessed for eligibility of whom 35 were excluded due to exclusion criteria or withdrawal (figure 1). This left 67 eligible patients for randomisation. However, before baseline testing additionally two patients in the HIIT group and four patients in the control group dropped out leaving 30 for allocation to the HIIT and 31 to the control group. More women than men were included in the study (70% and 65% in HIIT and control groups, respectively) and the mean age was 51 (SD 11) in the HIIT group and 45 (SD 12) years among controls. Baseline characteristics are presented in table 1.

The participants in the HIIT group delivered completed diaries for 95% of all the weeks. The completion of the guided exercises was 78% of sessions. However, they also did more self-guided endurance exercises than requested, that is, 1.2 times a week. According to diaries, the mean intensity during guided exercise was 16.4 (SD 3.3) referring to the Borg scale, which is considered ‘very hard’ effort. The intensity during self-guided exercise was 12.8 (SD 3.4) referring to the Borg scale, which is considered ‘moderate’ effort. At 9 months of follow-up, 28 participants remained in each arm. Of these, 12 (43 %) in the HIIT and 5 (18 %) in the control group reported at an interview that they were doing endurance exercise.

Effect on outcome measures at 3 months
The HIIT group had a 3.72 mL/kg/min (95% CI 2.38 to 5.06) higher VO_{2max} and 1.28% (95% CI −2.51 to −0.05) lower truncal fat mass than the control group (table 2). Adjusting for baseline BMI, the difference in VO_{2max} slightly increased to 3.82 mL/kg/min (95% CI 2.49 to 5.15). Adjusting for smoking status did not affect the estimated effect on VO_{2max}. In addition, there was also some evidence that the HIIT group had slightly lower total fat% (−0.80; 95% CI −1.71 to 0.10), BMI (−0.31; 95% CI −0.78 to 0.17), and resting HR (−3.5; 95% CI −7.6 to 0.6) than the control group. There was no difference in lean muscle mass between the groups (67 g; 95% CI −776 to 911) (table 2).
Outcome at 9 months of follow-up

At 9 months of follow-up, the effect on oxygen uptake was still evident with 3.08 mL/kg/min (95% CI 1.63 to 4.53) higher VO\textsubscript{2max} in the HIIT group than the control group. There were no major differences between the two groups for the other outcome measures (table 3), although total and truncal fat percentage declined in the HIIT group.

Safety

During the period of intervention from baseline to 3 months, two in the HIIT group and none in the control group had intra-articular injections. Injections were given 1 month after start of the intervention. At 3 months of follow-up, four patients in the HIIT group and three in the control group had intra-articular injections. In the 3 to 9 months of follow-up, four in the HIIT group and seven in the control group had intra-articular injections. None of the injections were given closer than 4 weeks prior to evaluations. One patient left the HIIT group due to sequelae after stroke previous to the study and found the intervention too hard. No other adverse events were reported during the intervention.

DISCUSSION

In this RCT, we observed a clear positive effect of HIIT on cardiorespiratory fitness and body composition in patients with PsA. The observed increase in VO\textsubscript{2max} corresponds to a 13.5% increase in the HIIT group, that is, 12.6% more than the control group at 3 months. Furthermore, there was an effect with a reduction in truncal fat mass. There was also some evidence that HIIT had favourable effects on other CVD risk factors, such as total fat mass, BMI and resting HR. At 9 months of follow-up, the effect on VO\textsubscript{2max} was still evident, and there was still
a reduced total and truncal fat mass in the HIIT group whereas the difference between the two groups was not as pronounced. Patients with PsA are considered to have an increased risk of CVD. However, it is still unclear to what extent this is caused by inflammation, traditional CVD risk factors or both. Further, patients with PsA are found to have an increased prevalence of several traditional CVD risk factors such as obesity, smoking, high triglyceride level, low HDL-c level and hypertension, indicating that reducing these risk factors will be of great importance as a supplement to disease-modifying treatment. Thus, improving cardiorespiratory fitness could be a means for prevention of CVD among these patients. Moreover, as patients with PsA are at risk of developing enthesis from mechanical stress, exposing them to vigorous exercise could result in an anticipated increase in disease activity. However, it is of importance to notice that the disease activity was stable as demonstrated in a recently published study from the same sample.

The observed effect on VO$_{2\text{max}}$ in line with previous studies of HIIT in otherwise healthy people, as well as in patients with heart disease and arthritis. In addition, the magnitude of the increase in VO$_{2\text{max}}$ in our patients exceeds the value that corresponds to a 13% decrease in all-cause mortality. Baseline VO$_{2\text{max}}$ in our patients was similar to that of healthy inactive people in Norway, indicating recruitment of patients with a sedentary lifestyle. Partially, the low VO$_{2\text{max}}$ could also be explained by a high BMI and a preponderance of women in the study, as individual VO$_{2\text{max}}$ is associated with age, gender and weight. Improving VO$_{2\text{max}}$ is important if the aim of physical exercise is to reduce the risk of CVD, as higher levels of cardiorespiratory fitness protect against CVD and all-cause mortality. In fact, low cardiorespiratory fitness is found to be a more powerful predictor of mortality than traditional risk factors, such as hypertension, smoking, obesity, hyperlipidemia and type 2 diabetes. In our study, there was a long-term effect on VO$_{2\text{max}}$ measured at 9 months’ follow-up, indicating that the effect on cardiorespiratory fitness could be maintained even with less training effort over time.

The observed reduction in fat percentage after HIIT is also in line with previous studies in which a marked effect on body composition with decreased total body fat and increased fatty acid oxidation has been demonstrated after 12 weeks of sprint interval training in untrained men and women, with a more pronounced effect in men. In patients with spondyloarthritis, the effect of HIIT and strength exercise for 3 months on body composition was evident in both genders. The more pronounced effect of sprint interval training on reduction in truncal fat percentage in men might be a result of the androgenic effect of sprint interval training. In our study, there was a long-term effect on VO$_{2\text{max}}$ measured at 9 months’ follow-up, indicating that the effect on cardiorespiratory fitness could be maintained even with less training effort over time.

Table 1: Baseline characteristics of patients with psoriatic arthritis in the intervention and control groups

|                                | Intervention (N=30) | Control (N=31) |
|--------------------------------|--------------------|---------------|
| **Demographics/medication**    |                    |               |
| Age, years, mean (SD)          | 50.5 (11.1)        | 44.9 (12.1)   |
| Female, n (%)                  | 21 (70)            | 20 (65)       |
| Disease duration, years, median (p25, p75) | 6 (2–12)          | 4 (2–11)      |
| Synthetic DMARDs, n (%)        | 28 (93)            | 25 (81)       |
| Biologic DMARDs, n (%)         | 11 (37)            | 9 (29)        |
| Antihypertensive, n (%)        | 4 (13)             | 4 (13)        |
| Statins, n (%)                 | 3 (10)             | 0 (0)         |
| Cardiovascular assessment      |                    |               |
| Current smoker, n (%)          | 6 (20)             | 4 (13)        |
| VO$_{2\text{max}}$ (mL/kg/min), mean (SD) | 28.73 (6.41)     | 30.75 (7.95)  |
| Resting HR (beats/min), mean (SD) | 65.3 (11.5)       | 66.4 (9.5)    |
| Systolic BP (mm Hg), mean (SD) | 124 (12)           | 125 (16)      |
| Diastolic BP (mm Hg), mean (SD) | 77 (8)             | 78 (11)       |
| Cholesterol (mmol/L), mean (SD) | 5.2 (0.8)          | 5.1 (1.0)     |
| Triglyceride (mmol/L), median (p25, p75) | 1.1 (0.8–1.9)    | 1.0 (0.7–1.4) |
| LDL (mmol/L), mean (SD)        | 3.2 (0.8)          | 3.3 (0.7)     |
| Body composition               |                    |               |
| BMI (kg/m²), mean (SD)         | 28.6 (4.2)         | 27.6 (4.4)    |
| Total fat%, mean (SD)          | 40.3 (7.1)         | 38.7 (7.7)    |
| Truncus fat%, mean (SD)        | 43.7 (8.2)         | 41.3 (8.7)    |
| Lean muscle mass (g), mean (SD) | 48 423 (10163)    | 48 436 (12066) |
| Waist circumference (cm), mean (SD) | 100.1 (10.5)     | 96.0 (13.8)   |
| Disease activity               |                    |               |
| HS-CRP (g/L), median (p25, p75) | 1.56 (0.9–4.5)    | 1.87 (0.86–4.74) |
| DAS44, mean (SD)               | 2.00 (0.79)        | 1.94 (0.76)   |
| Swollen joints, median (p25, p75) | 0 (0–1)           | 0 (0–2)       |
| Tender joints 66, median (p25, p75) | 5 (1–10)          | 6 (1–10)      |
| PGA (VAS 0–100), mean (SD)     | 38.4 (23.7)        | 41.6 (20.8)   |
| MHAQ, median (p25, p75)        | 0.32 (0.0–0.75)    | 0.25 (0.13–0.63) |

BM1, Body Mass Index; BP, blood pressure; DAS44, disease activity score of 44 joints; DMARD, disease-modifying antirheumatic drug; HR, heart rate; HS-CRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein; MHAQ, Modified Health Assessment Questionnaire; PGA, patient global assessment; VAS, Visual Analogue Scale; VO$_{2\text{max}}$, maximal oxygen uptake.

Thomsen RS, et al. RMD Open 2018;4:e000729. doi:10.1136/rmdopen-2018-000729
Table 2  Changes in outcome between the intervention group doing high-intensity interval training and the control group and changes within the groups from baseline to 3 months of follow-up

| N=61 | Baseline mean both groups | 3 months change from baseline | Mean difference between groups 3 months |
|------|---------------------------|-------------------------------|----------------------------------------|
|      | Control | Intervention |                           |                                       |
| Cardiorespiratory fitness |          |                |                           |                                       |
| VO$_{2\text{max}}$ (mL/kg/min) | 29.51 | 27.97 to 31.05 | 0.25 | 0.61 | 0.25 | 0.61 | 3.97 | 0.001 | 3.72 | 0.001 |
| HR (beats/min) | 65.8 | 63.3 to 68.3 | -1.0 | -4.0 | -1.0 | -4.0 | -4.5 | -7.6 to -1.4 | -3.5 | -7.6 to 0.6 |
| Body composition |          |                |      |       |      |       |      |        |       |        |
| Total fat% | 42.53 | 40.43 to 44.63 | -0.11 | -0.98 | -0.11 | -0.98 | -1.39 | -2.27 to -0.52 | -1.28 | -2.51 to -0.05 |
| Lean muscle mass (g) | 52.16 | 50.07 to 54.25 | 0.44 | 0.44 | 0.44 | 0.44 | 114 | 7.6 to 187 | 67 | 3.01 to 5.06 |
| Adjusted for age and sex. | | | | | | | | | | |
| BMI (kg/m²) | 28.10 | 27.07 to 29.14 | -0.40 | -0.38 | -0.40 | -0.38 | -0.35 | -0.69 to -0.01 | -0.31 | -0.78 to 0.17 |
| Lean muscle mass (g) | 48.46 | 46 | 0.88 | 64 | 0.88 | 64 | 114 | 7.6 to 187 | 67 | 3.01 to 5.06 |

Informing the patients that HIIT is a method of physical exercise that is less time consuming but more beneficial in improving cardiorespiratory fitness with an additive effect on fat metabolism could be a possible approach. A strength of this study was the randomised design, the use of objective outcome measures and that the assessors of the outcome measures were blinded to allocation. In addition, both groups had the same type and amount of follow-up and the diagnosis was confirmed before enrolment by an experienced rheumatologist. Furthermore, the training intervention was individualised with the same relative intensity according to the HIIT principle. In the HIIT group, the adherence to the guided exercise sessions was good and the exercises were performed with a high intensity according to the diaries. However, the controls were not delivering diaries and we have no information about their physical activity habits during the intervention period from baseline to 3 months. A potential increase in physical activity could imply a reduced difference in effect between the groups. The drop-out rate was only 6%–7% in both groups, which makes the estimates of effect from the intention-to-treat analyses more valid. Moreover, disease duration and disease activity measured by patient global assessment as well as medical treatment are comparable with that of other patients with PsA indicating a high external validity of our results. Nevertheless, patients who volunteer to participate in a trial involving physical exercise might be more experienced with and more motivated for physical activity and exercise than non-participants, hence reducing the generalisability of our results. In addition, performing physical exercise in groups might reinforce both the individual adherence and effort. Some other limitations of the study are worth mentioning, such as the relatively small sample size that reduces the precision of the estimated effects. The small sample size might also explain the baseline imbalance in age and sex with lower age and more men in the control group, which may have contributed to a slightly higher baseline VO$_{2\text{max}}$ among controls. However, all analyses were adjusted for baseline age and sex. Nevertheless, the joint baseline category between the intervention and control group could have attenuated the observed effect. Further, ideally all of the HIIT sessions ought to be guided, but for practical reasons and time constraints for the participants, only two of three exercises were supervised. This could have resulted in lower exercise intensities for the unsupervised sessions and consequently a smaller observed effect of HIIT between the groups. In addition, the controls were allowed to practise endurance exercises from 3 to 9 months to enhance their willingness to
participate in the study. This could mask potential long-term effects. However, only 5 of the 28 participants in the control group reported vigorous exercise during this period.

The differences in the estimates of effect regarding secondary outcomes might not be of clinical relevance. However, the study duration of 11 weeks was relatively short and with an extended duration of the intervention, one might expect an effect of clinical relevance especially regarding the reduction in truncal fat.

Finally, we cannot rule out that the reduction in fat percentage could partly be explained by a change towards a healthier lifestyle when it comes to diet, nutrition and overall physical activity. However, the lean muscle mass was unchanged, assuming that the reduction of fat mass was not mainly a result of dietary change since that might have caused a reduction in muscle mass as well.

CONCLUSION
In patients with PsA, 3 months with HIIT was associated with a substantial increase in VO_{2max} and a reduction in truncal fat percentage compared with controls. In addition, there was a long-term effect on the increase of VO_{2max}. This indicates that HIIT is also beneficial in patients with PsA in preventing CVD by increasing cardiopulmonary fitness and reducing abdominal fat.

Table 3 Changes in outcome between the intervention group doing high-intensity interval training and the control group and changes within the groups from baseline to 9 months of follow-up

| N=61 | Baseline mean both groups | 9 months change from baseline | Mean difference between groups 9 months |
|------|---------------------------|-----------------------------|----------------------------------------|
|      | Control | Intervention |                                  |                                        |
| Cardiorespiratory fitness | | | | |
| VO_{2max} (mL/kg/min) | 29.51 | 0.21 | 3.29 | 3.08 |
| 95% CI | 27.97 to 31.05 | -0.81 to 1.22 | 2.23 to 4.34 | 1.63 to 4.53 |
| P values | 0.69 | <0.001 | <0.001 | |
| HR (beats/min) | 65.8 | -0.4 | 1.9 | 2.2 |
| 95% CI | 63.3 to 68.3 | -3.4 to 2.7 | -1.2 to 4.9 | -1.9 to 6.3 |
| P values | 0.82 | 0.24 | 0.29 | |

Body composition

| N=61 | Baseline mean both groups | 9 months change from baseline | Mean difference between groups 9 months |
|------|---------------------------|-----------------------------|----------------------------------------|
|      | Control | Intervention |                                  |                                        |
| Truncal fat% | 42.53 | -0.17 | -1.08 | -0.92 |
| 95% CI | 40.43 to 44.63 | -1.03 to 0.70 | -1.96 to −0.21 | -2.14 to 0.31 |
| P values | 0.71 | 0.02 | 0.14 | |
| Total fat% | 39.48 | -0.29 | -0.80 | -0.50 |
| 95% CI | 37.91 to 41.05 | -0.93 to 0.35 | -1.44 to −0.16 | -1.41 to 0.40 |
| P values | 0.37 | 0.02 | 0.27 | |
| BMI (kg/m²) | 28.10 | 0.07 | -0.32 | -0.39 |
| 95% CI | 27.07 to 29.14 | -0.27 to 0.41 | -0.66 to 0.02 | -0.87 to 0.09 |
| P values | 0.67 | 0.07 | 0.11 | |
| Lean muscle mass (g) | 48 460 | -71 | -524 | -453 |
| 95% CI | 47 074 to 49 847 | -669 to 527 | -1125 to 76 | -1297 to 390 |
| P values | 0.82 | 0.09 | 0.29 | |

Adjusted for age and sex.
BMI, Body Mass Index; HR, resting heart rate; VO_{2max}, maximal oxygen uptake.

Author affiliations
1Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
2Department of Rheumatology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
3Department of Anaesthesia and Intensive Care, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
4Department of Neuroradiology and Movement Science, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
5Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway
6Department of Circulation and Medical Imaging, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
7St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
8Division of Rheumatology, Allergy, and Immunology, School of Medicine, University of California, San Diego, California, USA

Acknowledgements NeXt Move, Norwegian University of Science and Technology (NTNU), provided the testing of maximal oxygen uptake and maximum heart rate. NeXt Move is funded by the Faculty of Medicine and Health at NTNU and Central Norway Regional Health Authority. The authors would also like to thank the participating patients.

Contributors RST: conception and design of the trial, performing the trial, statistical analyses and interpretation of the data, writing. TILN: statistical analyses and interpretation of the data, writing. GH: interpretation of the data, writing. AB: design of the trial, writing. AK: interpretation of the data, writing. MH: conception and design of the trial, interpretation of the data, writing.

Funding RST has received a grant from The Norwegian ExtraFoundation for Health and Rehabilitation.

Disclaimer The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
REFERENCES

1. Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68:1131–5.

2. Jaye M, Ake et al in a healthy population: the HUNT study. Med Sci Sports Exerc 2012;44:1881–9.

3. Bakken AC, Torun Z, Anderson M, et al. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res 2017;69:67–74.

4. Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in health adults and women: a meta-analysis. JAMA 2009;301:2024–35.

5. Polaček A, Vlašnjeboim B, Kokkinos P, et al. Cardiorespiratory fitness versus physical activity as predictors of all-cause mortality in men. Am Heart J 2018;196:156–62.

6. Karlson T, Aamot IL, Haykowsky M, et al. High intensity interval training for maximizing health outcomes. Prog Cardiovasc Dis 2017;60:67–77.

7. Nesi BM, Järnskjärli I, Aspenes ST, et al. Exercise patterns and peak oxygen uptake in adults with rheumatoid arthritis. Arthritis Care Res 2012;64:1881–9.

8. Wisloff U, Støylen A, Loennechen JP, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation 2007;115:3086–94.

9. Bacon AP, Carter RE, Ogle EA, et al. VO2max trainability and high intensity interval training in humans: a meta-analysis. PLoS One 2013;8:e73182.

10. Hagel S, Lindqvist E, Brander A, et al. Team-based rehabilitation improves long-term aerobic capacity and health-related quality of life in patients with chronic inflammatory arthritis. Disabil Rehabil 2010;32:1686–96.

11. Iversen MD, Frits M, von Heideken J, et al. The impact of high intensity interval training on disease activity and patient disease perception in patients with psoriatic arthritis: a randomized controlled trial. Arthritis Care Res 2018.

12. Møgelvang J, Hettland E, Helgerud J, et al. High intensity aerobic interval exercise is superior to moderate intensity exercise for increasing aerobic capacity in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil 2004;11:216–22.

13. Sandstad J, Stensvold D, Hoff M, et al. The effects of high intensity interval training in women with rheumatoid arthritis: a pilot study. Eur J Appl Physiol 2015;115:2081–9.

14. Aspenes ST, Nilsen TI, Skaug EA, et al. Peak oxygen uptake and cardiovascular risk factors in 4631 healthy women and men. Med Sci Sports Exerc 2011;43:1465–73.

15. Myers J, Kaminsky LA, Haykowsky M, et al. A reference equation for normal standards for VO2 max: analysis from the Fitness Registry and the Importance of Exercise National Database (FRIEND Registry). Prog Cardiovasc Dis 2017;60:21–9.

16. Myers J, McAuley P, Lavelle C, et al. Physical activity and cardiorespiratory fitness as major markers of health: their independent and interwoven importance to health status. Prog Cardiovasc Dis 2015;57:306–14.

17. Nilsen TI, Aamot IL, Haykowsky M, et al. Exercise capacity and the risk of death in women: the ST James Women Take Heart Project. Circulation 2003;108:1542–9.

18. Williams PT. Physical fitness and activity as separate heart disease risk factors: a meta-analysis. Med Sci Sports Exerc 2001;33:7354–61.

19. Myers J, Kaykha A, George S, et al. Fitness versus physical activity patterns in predicting mortality in men. Am J Med 2004;117:912–8.

20. Bankar S, Stelm M, Capetivel S, et al. Association of changes in adipokines and focal insertion point inflammation. Exp Dermatol 2016;25:1305–11.

21. Landberg R, Ehrstedt M, Brandt L, et al. Increased prevalence of metabolic syndrome and adipokytokine levels in a psoriatic arthritis cohort. J Clin Rheumatol 2018;24:302–7.

22. Feld J, Nissan S, Eubanks E, et al. Increased prevalence of metabolic syndrome and adipokytokine levels in a psoriatic arthritis cohort. J Clin Rheumatol 2018;24:302–7.

23. Lee JJ, Pedley A, Hoffmann U, et al. Association of changes in abdominal fat quantity and quality with incident cardiovascular disease risk factors. J Am Coll Cardiol 2016;68:1698–2016.

24. Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol 2011;20:81–7.

25. Scotece M, Conde J, Gómez R, et al. Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases. Mediators Inflamm 2012;2012:125458–.

26. Hildesbrandt H, Hoffmann H, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008;359:2105–20.

27. Jacqmin C, Senvy H, Molto A, et al. Physical activity assessment using an activity tracker in patients with rheumatoid arthritis and axial spondyloarthropathy: prospective observational study. J Rheumatol 2016;6:1.
47. Katz P, Margarett M, Gregorich S, et al. Physical activity to reduce fatigue in rheumatoid arthritis: a randomized controlled trial. *Arthritis Care Res* 2018;70:1–10.

48. Tjonna AE, Leinan IM, Bartnes AT, et al. Low- and high-volume of intensive endurance training significantly improves maximal oxygen uptake after 10-weeks of training in healthy men. *PLoS One* 2013;8:e65382.

49. Michelsen B, Fiane R, Diamantopoulos AP, et al. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. *PLoS One* 2015;10:e0123582.

50. Desthieux C, Granger B, Balanescu AR, et al. Determinants of patient-physician discordance in global assessment in psoriatic arthritis: a multicenter European study. *Arthritis Care Res* 2017;69:1606–11.